摘要:
The present invention is in the field of coagulation diagnostics and relates to methods for detecting modulators of GPIb-thrombin interaction in a sample. To this end, the sample is contacted with isolated mutated GPIbα protein and thrombin, and the formation of a complex between mutated GPIbα protein and thrombin is determined.
摘要:
Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
摘要:
An automatic analysis system (1) for analyzing a sample (23), the analysis system (1) comprising a first device (2) for storing cartridges (3) at a first temperature (T1), the first temperature (T1) being less than 268.15 kelvin.
摘要:
Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
摘要:
The present invention is in the field of coagulation diagnostics and relates to methods for detecting modulators of GPIb-thrombin interaction in a sample. To this end, the sample is contacted with isolated mutated GPIbα protein and thrombin, and the formation of a complex between mutated GPIbα protein and thrombin is determined.
摘要:
The present invention is in the field of coagulation diagnostics and relates to methods for detecting modulators of GPIb-thrombin interaction in a sample. To this end, the sample is contacted with isolated mutated GPIbα protein and thrombin, and the formation of a complex between mutated GPIbα protein and thrombin is determined.
摘要:
Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
摘要:
The present invention is in the field of in vitro diagnostics and relates to a method for preparing lipemic plasma or serum samples and the use thereof for establishing a lipid interference in the quantitative determination of the amount or the activity of an analyte in a plasma or serum sample.
摘要:
The invention relates to a screening process for determining a disordered von Willebrand factor (VWF)-GPIb interaction in a patient's sample. This comprises contacting the sample with isolated GPIb.alpha. protein, with VWF protein and with a solid phase associated with an antibody specific for said isolated GPIb.alpha. protein, and determining complex formation.
摘要:
Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.